Financial Data and Key Metrics Changes - Total sales for Q2 2025 were $342 million, slightly above the high end of guidance, with year-over-year growth of 3.1% as reported and 2.9% in constant currency [6][19] - Adjusted net income for Q2 was $35.6 million, an increase of 16.4% year-over-year, and adjusted diluted net earnings per share were $1.15, up 17.3% year-over-year [7][22] - Adjusted gross margin for Q2 was 56.5%, which is 120 basis points higher than the prior year [20] Business Line Data and Key Metrics Changes - Worldwide general surgery sales grew by 4.4%, while worldwide orthopedic sales increased by 0.8% year-over-year [6][19] - AirSeal remains the largest contributor to general surgery growth, with a recurring revenue profile of 92% [8] - Buffalo Filter experienced double-digit growth, supported by legislative adoption and new product introductions [10] Market Data and Key Metrics Changes - U.S. general surgery sales grew by 4.3%, while international general surgery sales increased by 4.7% [19] - U.S. orthopedic sales decreased by 0.8%, while international orthopedic sales grew by 1.8% [19] - The global smoke evacuation market is estimated to be approximately $300 million today, with potential growth to $2 billion in the coming years [11] Company Strategy and Development Direction - The company is focused on building a stronger operational foundation to support long-term growth and deliver value [14] - Key priorities include stabilizing and scaling operations, driving efficiencies, and building a high-performance supply chain [15][16] - The company aims to maintain a strong balance sheet and reduce debt, expecting the leverage ratio to fall below 3.0 by the end of 2025 [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in business fundamentals and long-term strategy, actively optimizing the portfolio towards higher margin opportunities [17] - The company anticipates gradual improvement in growth rates in the second half of the year, with expectations of lower capital headwinds [43] - Management noted that supply chain challenges are being addressed, with expectations of a significantly improved position by the end of the year [33] Other Important Information - The company is committed to maintaining a strong balance sheet and reducing debt, with a focus on higher margin, high growth opportunities [17][16] - Capital expenditures in Q2 were $5.7 million, compared to $3.6 million a year ago [23] Q&A Session Summary Question: Has there been increased competition in the Buffalo Filter market? - Management noted that there have not been new players entering the market, and competition remains the same despite legislative tailwinds [30] Question: What is the current status of supply chain constraints and Salesforce expansion? - Management indicated progress in resolving supply chain issues and mentioned that sales professionals are typically added dynamically throughout the year [32][34] Question: How is the capital market performing, and what trends are being observed? - Management stated that capital demand from hospitals remains strong, but supply chain challenges have impacted capital flow [38] Question: How does the company view its share position in orthopedics amid supply constraints? - Management acknowledged a loss of market share but emphasized ongoing innovation and the strength of the Biobrace platform [40][41] Question: Can you clarify the guidance for the next two quarters? - Management expects gradual improvement in growth rates and has raised the bottom end of the revenue guidance while keeping the top end the same [43][44] Question: What factors contributed to the increase in EPS guidance? - The increase in EPS guidance was attributed to improvements in margins, currency effects, and operational performance [45]